Table 3.
Univariate and multivariate analyses of clinical parameters in 28 NSCLC patients with BRAF mutation on overall survival
| Factor | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR (log rank) | 95% CI | P value | HR (log rank) | 95% CI | P value | |
| Gender (Female/Male) | 0.527 | 0.193–1.090 | 0.094 | 0.590 | 0.235–1.481 | 0.261 |
| Age (<65/≥65) | 1.172 | 0.529–2.634 | 0.692 | |||
| Smoking (Never/Smoking) | 0.343 | 0.044–0.613 | 0.011 | 0.378 | 0.117–1.221 | 0.104 |
| Histology (Adeno/Non‐adeno) | 0.390 | 0.036–1.297 | 0.104 | |||
| PS (0‐1/>1) | 0.279 | 0.032–0.367 | 0.001 | 0.208 | 0.071–0.607 | 0.004 |
| Co‐occurring driver (Yes/No) | 0.785 | 0.287–2.096 | 0.638 | |||
| BRAF mutation (V600E/non‐V600E) | 1.737 | 0.602–4.468 | 0.349 | |||
HR, hazard ratio; CI, confidence interval; Adeno, adenocarcinoma; PS, performance score.